Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Laboratory StudyEx vivo cell cultureContinuous exposure
Human hair follicles and dermal papilla cells studied outside the body
AHK-Cu was tested across 10^-13 to 10^-7 molar concentrations during a 12-day hair-follicle culture experiment
This is laboratory exposure, not topical or injectable human dosing. No controlled systemic administration quantity was identified.
View sourceEvidence summary
A copper-binding tripeptide investigated mainly in laboratory and cosmetic hair or skin contexts. Evidence does not establish a systemic injectable protocol.
Protocol basis
The available evidence is formulation-specific and predominantly preclinical, so no topical-to-injectable conversion is presented.
What remains uncertain
Systemic safety, human pharmacokinetics, dose-response and product equivalence are unknown.
Warnings and contraindications
Topical or cell-culture findings do not validate subcutaneous administration.
Copper exposure and peptide complex stability depend on formulation.
No controlled human injectable regimen was identified.